Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Almac, DSM Advance Biocatalysis Pact | Contract Pharma
Breaking News, Collaborations & Alliances

Almac, DSM Advance Biocatalysis Pact

Provides access to enzyme technologies and services for API manufacture

A collaboration between Almac and DSM Pharmaceutical Products in the field of biocatalysis to provide sustainable manufacturing services to the pharma industry, has successfully transferred enzymes for enzyme screening, process development and scale-up manufacture. The companies have completed multiple projects in the fields of ketoreductase, transaminase, bioöixdation and hydrolase.
 
The agreement grants both parties access to enzyme platform technologies and services for the manufacture of APIs and combines Almac’s rapid enzyme identification, scale-up and implementation into early phase projects, with DSM’s commercial manufacturing bioprocesses run on a multi-ton scale.
 
Dr. Tom Moody, head of Almac Biocatalysis, said, “The success of the projects undertaken between Almac and DSM already demonstrates there is a market for scalable green technologies to access difficult-to-make chiral chemicals.  Cost remains a prevalent issue within the industry and the introduction of enzymes into processes earlier in the drug discovery pipeline helps to drive cost down as projects move forward. Our collaboration is delivering real rewards to clients from both a technical and financial perspective.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters